insights_auto
为什么 ALTME 下跌了 4.50%?
深入探索chevron_right
ALTME:EPA
TME Pharma NV
€0.11
arrow_downward
-4.50%(-0.0050) 1 天
10月20日, GMT+2 17:35:13 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ALTME 生成关键数据洞见…
开盘价
€0.11
最高价
€0.11
最低价
€0.10
市值
996.87万
平均成交量
185.39万
成交量
19.91万
52 周最高价
€0.17
52 周最低价
€0.05
每股收益
-€0.03
员工人数
0
开盘价
€0.11
最高价
€0.11
最低价
€0.10
市值
996.87万
平均成交量
185.39万
成交量
19.91万
52 周最高价
€0.17
52 周最低价
€0.05
每股收益
-€0.03
员工人数
0
新闻报道
来自网络来源和新闻合作伙伴
www.tmgm.com
·
34分钟前
道琼斯工业平均指数受财报及原油价格走低提振上涨
Traders Union
·
8小时前
Ben Carlson指出，标普500指数前10大股票占总市值的40%
TradingKey
·
16小时前
美股收盘：道指升超500点，美伊谈判消息反复；部分科技股反弹，Meta连跌5日
资料
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
TME Pharma NV简介